Healthcare provider profile · identity verified

Vibhu Dhingra, MD

Internal Medicine · CHARLOTTE, NC · NPI 1053677930

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	595	168
Amlodipine Besylate	Amlodipine Besylate	497	130
Losartan Potassium	Losartan Potassium	308	91
Omeprazole	Omeprazole	211	70
Rosuvastatin Calcium	Rosuvastatin Calcium	205	64
Lisinopril	Lisinopril	203	56
Gabapentin	Gabapentin	191	52
Metoprolol Succinate	Metoprolol Succinate	188	55
Levothyroxine Sodium	Levothyroxine Sodium	168	43
Tamsulosin Hcl	Tamsulosin Hcl	156	51
Metformin Hcl Er	Metformin Hcl	155	47
Hydrochlorothiazide	Hydrochlorothiazide	149	42
Albuterol Sulfate Hfa	Albuterol Sulfate	130	43
Fluticasone Propionate	Fluticasone Propionate	128	54
Eliquis	Apixaban	100	24
Pantoprazole Sodium	Pantoprazole Sodium	97	31
Sertraline Hcl	Sertraline Hcl	96	23
Trazodone Hcl	Trazodone Hcl	91	30
Jardiance	Empagliflozin	90	29
Metformin Hcl	Metformin Hcl	87	27
Pravastatin Sodium	Pravastatin Sodium	82	28
Alendronate Sodium	Alendronate Sodium	79	28
Famotidine	Famotidine	79	26
Furosemide	Furosemide	75	26
Alprazolam	Alprazolam	73	20
Rybelsus	Semaglutide	71	17
Carvedilol	Carvedilol	66	18
Synthroid	Levothyroxine Sodium	65	11
Allopurinol	Allopurinol	60	19
Potassium Chloride	Potassium Chloride	60	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	58	suppressed
Montelukast Sodium	Montelukast Sodium	58	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	56	15
Meloxicam	Meloxicam	53	23
Clopidogrel	Clopidogrel Bisulfate	52	16
Ozempic	Semaglutide	52	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	50	19
Simvastatin	Simvastatin	50	13
Citalopram Hbr	Citalopram Hydrobromide	47	11
Escitalopram Oxalate	Escitalopram Oxalate	47	15
Metoprolol Tartrate	Metoprolol Tartrate	47	14
Duloxetine Hcl	Duloxetine Hcl	46	14
Ibuprofen	Ibuprofen	46	11
Spironolactone	Spironolactone	44	14
Triamcinolone Acetonide	Triamcinolone Acetonide	44	21
Chlorthalidone	Chlorthalidone	41	11
Mounjaro	Tirzepatide	39	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	38	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	37	15
Tramadol Hcl	Tramadol Hcl	37	15
Olmesartan Medoxomil	Olmesartan Medoxomil	35	suppressed
Myrbetriq	Mirabegron	34	suppressed
Glipizide Er	Glipizide	33	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	11
Ezetimibe	Ezetimibe	31	13
Xarelto	Rivaroxaban	30	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Ventolin Hfa	Albuterol Sulfate	27	suppressed
Ondansetron Odt	Ondansetron	26	13
Clonazepam	Clonazepam	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Ketoconazole	Ketoconazole	25	14
Valacyclovir	Valacyclovir Hcl	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Repatha Sureclick	Evolocumab	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Finasteride	Finasteride	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Lovastatin	Lovastatin	22	suppressed
Novolog Flexpen	Insulin Aspart	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Tradjenta	Linagliptin	21	suppressed
Azelastine Hcl	Azelastine Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	16
Azithromycin	Azithromycin	19	17
Celecoxib	Celecoxib	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Combigan	Brimonidine Tartrate/Timolol	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	13
Doxycycline Hyclate	Doxycycline Hyclate	18	16
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	18	suppressed
Diazepam	Diazepam	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Torsemide	Torsemide	16	suppressed
Gemtesa	Vibegron	15	suppressed
Methylprednisolone	Methylprednisolone	15	13
Estradiol	Estradiol	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Klor-Con M20	Potassium Chloride	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	13
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	13	suppressed
Nystatin	Nystatin	13	suppressed
Ramipril	Ramipril	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Naproxen	Naproxen	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Latanoprost	Latanoprost	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error